Subscribe To
ASND / Ascendis Pharma A/S' (ASND) CEO Jan Mikkelsen on Q4 2021 Results - Earnings Call Transcript
ASND News
By Zacks Investment Research
October 26, 2023
Ascendis Pharma A/S (ASND) Loses -8.26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Ascendis Pharma A/S (ASND) as it is technically in oversold territory now. In addition to this tec more_horizontal
By Zacks Investment Research
September 15, 2023
Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock?
Ascendis Pharma A/S (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might h more_horizontal
By Seeking Alpha
September 5, 2023
Ascendis Pharma A/S (ASND) Q2 2023 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q2 2023 Earnings Conference Call September 5, 2023 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Rela more_horizontal
By Zacks Investment Research
August 10, 2023
How Much Upside is Left in Ascendis Pharma A/S (ASND)? Wall Street Analysts Think 47.35%
The mean of analysts' price targets for Ascendis Pharma A/S (ASND) points to a 47.4% upside in the stock. While this highly sought-after metric has no more_horizontal
By Proactive Investors
May 1, 2023
Ascendis Pharma shares pop after FDA rejects hormone therapy application but not the underlying clinical data
The US Food and Drug Administration (FDA) did not grant its approval to Ascendis Pharma's experimental hormone disorder therapy, but the company's sto more_horizontal
By Seeking Alpha
April 27, 2023
Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript. more_horizontal
By Seeking Alpha
April 16, 2023
Ascendis Pharma: Recent FDA Setbacks Present A Buying Opportunity
We are upgrading from a hold to buy rating for ASND following a 35% drop in stock price after FDA deficiency findings in the NDA for TransCon PTH for more_horizontal
By Zacks Investment Research
April 12, 2023
Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?
Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisio more_horizontal